{
    "ticker": "FOLD",
    "name": "Amicus Therapeutics, Inc.",
    "description": "Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering innovative treatments for rare and orphan diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, Amicus is dedicated to transforming the lives of patients with debilitating genetic disorders. The company's lead product candidate, Galafold (migalastat), is designed for the treatment of Fabry disease, a lysosomal storage disorder, and has been approved in multiple countries, including the United States and Europe. Amicus is also advancing a robust pipeline of therapies aimed at treating other rare diseases, including Pompe disease and other lysosomal storage disorders, through its cutting-edge gene therapy and pharmacological chaperone technology platforms. The company collaborates with various stakeholders, including patient advocacy groups and research institutions, to enhance its understanding of these rare diseases and to support the patient community. With a commitment to scientific excellence and patient-centricity, Amicus Therapeutics strives to make a significant impact in the field of rare disease treatment.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cranbury, New Jersey, USA",
    "founded": "2002",
    "website": "https://www.amicustherapeutics.com",
    "ceo": "John F. Crowley",
    "social_media": {
        "twitter": "https://twitter.com/amicustherapeutics",
        "linkedin": "https://www.linkedin.com/company/amicus-therapeutics/"
    },
    "investor_relations": "https://investors.amicustherapeutics.com",
    "key_executives": [
        {
            "name": "John F. Crowley",
            "position": "CEO"
        },
        {
            "name": "Bradley L. Campbell",
            "position": "President"
        },
        {
            "name": "Michael A. Raab",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Approved Therapies",
            "products": [
                "Galafold"
            ]
        },
        {
            "category": "Pipeline Products",
            "products": [
                "AT-GAA (Pompe Disease)",
                "AT-ONC (Gene Therapy)"
            ]
        }
    ],
    "seo": {
        "meta_title": "Amicus Therapeutics, Inc. | Innovative Treatments for Rare Diseases",
        "meta_description": "Amicus Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, including Fabry disease. Explore our mission and pipeline.",
        "keywords": [
            "Amicus Therapeutics",
            "Rare Diseases",
            "Fabry Disease",
            "Biotechnology",
            "Gene Therapy",
            "Pompe Disease"
        ]
    },
    "faq": [
        {
            "question": "What does Amicus Therapeutics focus on?",
            "answer": "Amicus Therapeutics focuses on developing treatments for rare and orphan diseases."
        },
        {
            "question": "What is Galafold?",
            "answer": "Galafold is an approved therapy for the treatment of Fabry disease."
        },
        {
            "question": "Where is Amicus Therapeutics headquartered?",
            "answer": "Amicus Therapeutics is headquartered in Cranbury, New Jersey, USA."
        },
        {
            "question": "When was Amicus Therapeutics founded?",
            "answer": "Amicus Therapeutics was founded in 2002."
        }
    ],
    "competitors": [
        "REGN",
        "BIIB",
        "NVS",
        "VRTX"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}